Action Tiziana Life Sciences - TLSA

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

Dernier

0,672

Prix Achat

0,68

Prix Vente

0,80

Volume échangé

689 194

0,6505 Fourchette du Jour 0,80

0,00 Plage de 52 semaines 0,00

Clôture Veille

0,6996

Ouverture

0,77

Dernière Transaction

100

0.672

(formt)

Dernière heure de transaction

01:17:34

Volume moyen (3 m)

Volume financier

US$ 470 925

VWAP

0,683298

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Tiziana Life Sciences Announces First Patient with Moderate Alzheimer’s Disease Dosed with Intranasal Foralumab

NEW YORK, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Tiziana Life Sciences Expands Phase 2 Clinical Trial for Non-Active Secondary Progressive Multiple Sclerosis to Additional Prestigious U.S. Medical Centers

NEW YORK, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Tiziana Life Sciences Announces Groundbreaking ALS Trial Grant Awarded by the ALS Association

NEW YORK, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Tiziana Life Sciences to Participate in BIO-Europe 2024 to Discuss Recent Clinical Advancements, Including Positive GLP-1 Combination Study Data

NEW YORK, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies...

Form 424B5 - Prospectus [Rule 424(b)(5)]

Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $10 Million

NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

TLSA - Frequently Asked Questions (FAQ)

What is the current Tiziana Life Sciences share price?

The current share price of Tiziana Life Sciences is US$ 0,672

What is the 1 year trading range for Tiziana Life Sciences share price?

Tiziana Life Sciences has traded in the range of US$ 0,00 to US$ 0,00 during the past year

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
VINCVincerx Inc	US$ 0,32 (64,95%)	23,04M
AERTAeries Technology Inc	US$ 1,39 (58,51%)	1,96M
CCTGCCSC Technology International Holdings Ltd	US$ 2,45 (49,39%)	3,11M
ARTWArts Way Manufacturing Co Inc	US$ 3,28 (34,43%)	242,28k
VRPXVirpax Pharmaceuticals Inc	US$ 0,501 (22,20%)	2,26M
LITMSnow Lake Resources Ltd	US$ 1,10 (-31,25%)	9,69M
XAIRBeyond Air Inc	US$ 0,38 (-13,64%)	1,9M
SHMDSCHMID Group NV	US$ 2,75 (-12,42%)	24,28k
COEPCoeptis Therapeutics Holdings Inc	US$ 0,1601 (-12,13%)	340,97k
AVGRAvinger Inc	US$ 0,85 (-11,92%)	271,51k
VINCVincerx Inc	US$ 0,32 (64,95%)	23,04M
CEROCERo Therapeutics Holdings Inc	US$ 0,0628 (4,67%)	15,27M
XTIAXTI Aerospace Inc	US$ 0,0414 (4,81%)	13,19M
LITMSnow Lake Resources Ltd	US$ 1,10 (-31,25%)	9,69M
INTZIntrusion Inc	US$ 1,94 (-10,19%)	7,78M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Tiziana Life Sciences Ltd (TLSA)

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

TLSA Dernières nouvelles

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Tiziana Life Sciences Announces First Patient with Moderate Alzheimer’s Disease Dosed with Intranasal Foralumab

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Tiziana Life Sciences Expands Phase 2 Clinical Trial for Non-Active Secondary Progressive Multiple Sclerosis to Additional Prestigious U.S. Medical Centers

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Tiziana Life Sciences Announces Groundbreaking ALS Trial Grant Awarded by the ALS Association

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Tiziana Life Sciences to Participate in BIO-Europe 2024 to Discuss Recent Clinical Advancements, Including Positive GLP-1 Combination Study Data

Form 424B5 - Prospectus [Rule 424(b)(5)]

Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $10 Million

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Tiziana Life Sciences Announces First Patient with Moderate Alzheimer’s Disease Dosed with Intranasal Foralumab

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Tiziana Life Sciences Expands Phase 2 Clinical Trial for Non-Active Secondary Progressive Multiple Sclerosis to Additional Prestigious U.S. Medical Centers

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Tiziana Life Sciences Announces Groundbreaking ALS Trial Grant Awarded by the ALS Association

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Tiziana Life Sciences to Participate in BIO-Europe 2024 to Discuss Recent Clinical Advancements, Including Positive GLP-1 Combination Study Data

TLSA - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Tiziana Life Sciences Ltd (TLSA) Cours

Tiziana Life Sciences Ltd (TLSA)

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

TLSA Dernières nouvelles

TLSA - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR